Drug Profile
Research programme: Huntington's disease therapeutics - FORUM Pharmaceuticals
Alternative Names: EVP-3546; EVPK-0003546Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator EnVivo Pharmaceuticals
- Developer FORUM Pharmaceuticals
- Class Quinazolines; Small molecules
- Mechanism of Action NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Huntington's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Huntington's-disease in USA
- 01 Jun 2016 Discontinued - Preclinical for Huntington's disease in USA (unspecified route)
- 02 Apr 2014 EnVivo Pharmaceuticals is now called FORUM Pharmaceuticals